Wunderlich raised its price target for Yelp (YELP) shares to $105 to reflect the company's strategic deal with YP and its recent integration into Yahoo's (YHOO) local search results. The firm keeps a Buy rating on Yelp.
Bristol-Myers Squibb’s market capitalization has dropped so much over the past year that it is now arguably no longer part of the big pharma club. After reporting disappointing earnings figures on Thursday, the company’s shares fell sharply, giving it a market capitalization of about $95 billion. The problem for Bristol-Myers is that its older blockbuster products, cancer drug Revlimid and blood thinner Eliquis, are expected to decline in the coming years and investors aren’t convinced that the company has enough growth drivers in the near term.
(Reuters) -GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.
The headline numbers for Hertz Global (HTZ) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Hertz Global (HTZ) delivered earnings and revenue surprises of -184.44% and 2.83%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Besides Wall Street's top -and-bottom-line estimates for Lilly (LLY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Are you tired of relying solely on dividend stocks for passive income? While they can be a great source of cash flow, putting all your eggs in the stock market basket comes with serious risks. Just look at what happened with AT&T Inc. (NYSE:T) in ...
New York Community Bancorp will have to lure buyers for its commercial real estate (CRE) loans with steep discounts and diversify its revenue as it races to shore up its finances. The bank's new management has promised to unveil a turnaround plan this month after losses on CRE loans, NYCB's core business, sparked a rout that wiped nearly $6 billion off its market value and sparked ratings downgrades. A $1 billion investment led by former U.S. Treasury Secretary Steven Mnuchin's Liberty Strategic Capital has shored up the bank for the short-term, but it still needs to bolster its capital and shrink its exposure to the CRE sector, which has been hammered by higher interest rates.